FIELD: medicine.
SUBSTANCE: pharmaceutical composition contains alimemazine as an active component, and target adjuvants: lactose, potato starch, microcrystalline cellulose, kollidon, magnesium stearate in the following ratio. The composition is made in the form of coated tablets with the coating containing polyvinyl alcohol, talc, polyethylene glycol, titanium dioxide, acceptable dying agents.
EFFECT: pharmaceutical composition extends range of medical products, meets all of the standard requirements and has shelf-life of 2 years.
5 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION OF PROLONGED ACTION FOR CORRECTION OF PSYCHOSOMATIC MANIFESTATIONS | 2009 |
|
RU2424807C2 |
| PHARMACEUTICAL COMPOSITION OF PROLONGED ACTION BASED ON CLOZAPINE OF PERORAL INTRODUCTION | 2009 |
|
RU2414903C1 |
| METHOD FOR PRODUCTION OF CLOZAPINE PHARMACEUTICAL COMPOSITION IN FORM OF TABLETS AND PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2441651C1 |
| PHARMACEUTICAL COMPOSITION IN FORM OF HARD PERORAL DRUG FOR TREATMENT OF GASTROINTESTINAL TRACT DISEASES | 2009 |
|
RU2418576C2 |
| RETARD TABLETS OF TRIMEBUTINE | 2013 |
|
RU2536254C1 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING MENTAL, BEHAVIOUR AND COGNITIVE DISORDERS | 2012 |
|
RU2488388C1 |
| PHARMACEUTICAL COMBINATION OF ATORVASTATIN AND NICERGOLIN FOR PREVENTING OR TREATING CEREBROVASCULAR DISEASE | 2011 |
|
RU2481124C1 |
| NADH COMPOSITION HAVING ANTIOXIDANT PROPERTIES | 2014 |
|
RU2545920C1 |
| AGENT FOR TREATING FUNCTIONAL GASTROINTESTINAL DISEASES | 2020 |
|
RU2740750C1 |
| ORAL GINDARINE MEDICINE AND PRODUCTION METHOD | 2007 |
|
RU2360675C1 |
